Powered by
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …
GRAND RAPIDS—Tetra Discovery Partners, a clinical-stage biotechnology company, announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s transition from a company focused on discovery research …
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. …
(Updated June 5 with stock price) ROCHESTER—OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital communication services for pharmaceutical companies to patients and healthcare providers, has announced a proposed underwritten …
ANN ARBOR—An Ann Arbor company that has developed a system to screen cancer patients to precision-designed treatments that will be most effective for them has a new clinical development collaboration …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), the digital health messaging provider for the pharmaceutical industry, announced its latest platform integration with the health care industry’s leading acute electronic health record (EHR) systems, …
CANTON TWP. – TrialAssure, a clinical trial management software developer, announced the limited release of Anonymize.DS, an all-new software-as-a-service application that allows sponsors to anonymize clinical trial data automatically. “In …
ROCHESTER — OptimizeRx Corp. (NASDAQ: OPRX), the Rochester-based provider of digital health messaging for the pharmaceutical industry, reported net income of $226,344 for the full year 2018, vs. a loss …
ROCHESTER — OptimizeRx Corp. (NASDAQ: OPRX), the Rochseter-based provider of digital health messaging for the pharmaceutical industry, announced a new partnership with Birmingham, Ala.-based IllumiCare Inc., developers of technology that …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedoic acid. The …